Try our Advanced Search for more refined results

October 19, 2020

Seagen Inc. v. Daiichi Sankyo Co., Ltd.

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 17, 2024

    PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict

    The Patent Trial and Appeal Board has said Daiichi Sankyo was able to show that the challenged claims of a Seagen cancer drug patent, which a Texas federal jury found Daiichi infringed in a $42 million verdict in 2022, were invalid.

10 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!